{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:11:25Z","timestamp":1772179885330,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jhep.2020.09.016","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T10:20:55Z","timestamp":1607509255000},"page":"753-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-9464","authenticated-orcid":false,"given":"Staffan","family":"Wahlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cumali","family":"Efe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2020.09.016_bib1","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group","volume":"73","author":"Lohse","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2020.09.016_bib2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/apt.15157","article-title":"Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","volume":"49","author":"Santiago","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.016_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MEG.0000000000001019","article-title":"A\u00a0systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment","volume":"30","author":"De Lemos-Bonotto","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.09.016_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/00365521.2018.1551498","article-title":"A\u00a0review of the utility of tacrolimus in the management of adults with autoimmune hepatitis","volume":"54","author":"Hanouneh","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.016_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.31407","article-title":"Immunosuppressive treatment regimens in autoimmune hepatitis: systematic reviews and meta-analyses supporting American Association for the Study of Liver Diseases guidelines","volume":"72","author":"Vierling","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.016_bib6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhep.2020.09.016_bib7","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2020.09.016_bib8","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s10620-018-5011-x","article-title":"Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis","volume":"63","author":"Efe","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.jhep.2020.09.016_bib9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.09.016_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee position statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782033628X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782033628X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:21Z","timestamp":1759174881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782033628X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S016882782033628X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.09.016","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.07.023","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}